NEUROENDOCRINE NEOPLASMS
Clinical trials for NEUROENDOCRINE NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE NEOPLASMS trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody drug aims to shrink hard-to-treat lung cancers
Disease control Recruiting nowThis study tests an experimental drug called BI 764532 (obrixtamig) in adults with advanced small cell lung cancer or other neuroendocrine cancers that have stopped responding to treatment. The drug is designed to help the immune system attack cancer cells. The main goals are to …
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New drug shows promise for rare cancer in large Real-World study
Disease control Recruiting nowThis study is testing a drug called surufatinib in about 350 adults with advanced neuroendocrine tumors, a type of cancer. The goal is to see how well the drug controls the cancer and what side effects it causes when used in everyday medical practice. Participants take the drug d…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE4 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New drug combo aims to shrink rare gut tumors
Disease control Recruiting nowThis study tests whether combining two drugs, Lutathera and Olaparib, can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive Lutathera by IV every 8 weeks and take Olaparib pills twice daily. The goal is to fi…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New hope for rare cancer: radioactive drug targets Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a radioactive drug called Lu-177-DOTATATE in people with rare tumors (pheochromocytoma or paraganglioma) that cannot be removed by surgery. The goal is to see if the drug can slow or stop tumor growth and to check its safety. About 130 adults will receive four do…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New imaging study tracks cancer drug's journey in patients
Knowledge-focused Recruiting nowThis study looks at how the medicine BI 764532 moves through the body and reaches tumors in people with advanced small cell lung cancer or other neuroendocrine cancers. About 12 adults who have not responded to other treatments will receive the drug and undergo PET scans to track…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:56 UTC